Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 12/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 12/20 | 0.62 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.53 |
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7424626 | 0.87 | PDE4A (0.66) | TAS1R3TAS1R1BCL2L1PDE4APDE4B | |
| SCHEMBL8323597 | 0.87 | PDE4A (0.66) | TAS1R3TAS1R1BCL2L1PDE4APDE4B | |
| SCHEMBL19083996 | 0.85 | TAS1R3 (0.64) | TAS1R3TAS1R1TOP2APDE4APDE4B | |
| SCHEMBL19083821 | 0.83 | TAS1R3 (0.53) | TAS1R3TAS1R1TOP2APDE4APDE4B | |
| SCHEMBL700709 | 0.77 | TAS1R3 (1.00) | TAS1R3TAS1R1BCL2L1 | |
| SCHEMBL703468 | 0.77 | TAS1R3 (1.00) | TAS1R3TAS1R1BCL2L1 | |
| SCHEMBL703467 | 0.77 | TAS1R3 (1.00) | TAS1R3TAS1R1BCL2L1 | |
| SCHEMBL700708 | 0.77 | TAS1R3 (1.00) | TAS1R3TAS1R1BCL2L1 | |
| SCHEMBL701392 | 0.76 | TAS1R3 (0.76) | TAS1R3TAS1R1BCL2L1 | |
| SCHEMBL702502 | 0.76 | TAS1R3 (0.76) | TAS1R3TAS1R1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | TAS1R3 2742/4885TAS1R1 2598/4885BCL2L1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.